Active Not Recruiting PHASE3 INTERVENTIONAL 1-arm NCT06696443

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Diabetic Peripheral Neuropathic Pain

Interventions Suzetrigine

Updated 13 times since 2024 Last updated: Jan 27, 2026 Started: Dec 18, 2024 Primary completion: Jan 25, 2027 Completion: Jan 25, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06696443, this PHASE3 trial focuses on Diabetic Peripheral Neuropathic Pain and remains ongoing. Sponsored by Vertex Pharmaceuticals Incorporated, it has been updated 13 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

13 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE3

Status: Enrolling By Invitation → Active Not Recruiting
Jan 2026 — Feb 2026 [monthly]

Enrolling By Invitation PHASE3
Nov 2025 — Jan 2026 [monthly]

Enrolling By Invitation PHASE3
Oct 2025 — Nov 2025 [monthly]

Enrolling By Invitation PHASE3
Sep 2025 — Oct 2025 [monthly]

Enrolling By Invitation PHASE3

▶ Show 8 earlier versions

Jul 2025 — Sep 2025 [monthly]

Enrolling By Invitation PHASE3
Jun 2025 — Jul 2025 [monthly]

Enrolling By Invitation PHASE3
May 2025 — Jun 2025 [monthly]

Enrolling By Invitation PHASE3
Apr 2025 — May 2025 [monthly]

Enrolling By Invitation PHASE3
Mar 2025 — Apr 2025 [monthly]

Enrolling By Invitation PHASE3
Feb 2025 — Mar 2025 [monthly]

Enrolling By Invitation PHASE3
Jan 2025 — Feb 2025 [monthly]

Enrolling By Invitation PHASE3

Status: Not Yet Recruiting → Enrolling By Invitation
Dec 2024 — Jan 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vertex Pharmaceuticals Incorporated

Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Anderson, United States , Anniston, United States , Baton Rouge, United States , Beachwood, United States , Bellevue, United States , Boston, United States , Brooklyn, United States , Charleston, United States , Chicago, United States and 53 more locations